Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Prior treatment

• Current or planned use of an open-label PCSK9 inhibitor during the study
• Any prior treatment with inclisiran
• Active or planned participation in another clinical study involving investigational drugs or devices during the study
• Patients taking prohibited therapies as listed in Section 6.6.3

Other illness

• Any serious liver disease, metabolic disease, neoplasm, end-stage kidney disease, or other condition in the opinion of the investigator that would inhibit trial participation or confound trial results

Other

• Planned future PCI or PVI
• Any other reason why, in the opinion of the investigator, the participant would not be suitable for study participation including safety considerations and the ability to adhere to protocol activities
• Pregnant or breast-feeding women

• Signed informed consent must be obtained prior to participation in the study.
• Males or females ≥ 18 years of age
• Within 14 days of a successful percutaneous coronary intervention (PCI) or peripheral endovascular intervention (PVI) for symptomatic CAD or lower extremity PAD
• Patients undergoing planned staged interventions are eligible for randomization only after the last planned intervention